ARTELO BIOSCIENCES, INC. Deferred Costs, Current
ARTELO BIOSCIENCES, INC. (ARTL) had Deferred Costs, Current of $291.67 thousand as of 2019-05-31, per its 10-Q filed 2019-07-15.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2019-07-15
- 2019-05-31: Deferred Costs, Current $291.67K.
| Period end | Deferred Costs, Current |
|---|---|
| 2019-05-31 | $291.67K 10-Q · filed 2019-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |